FLAG方案与CAG方案治疗复发、难治性急性髓系白血病的疗效比较

目的：评价并比较FLAG方案与CAG方案治疗复发、难治性急性髓系白血病（acute myeloid leukemi-a,AML）的疗效及安全性。方法：将2004年1月至2011年3月于我院接受化疗的复发、难治性AML患者74例,按治疗方案分成FLAG组和CAG组,对2组的疗效及不良反应进行分析比较。结果：FLAG组完全缓解率（CR）为61.5%,总有效率为76.9%;CAG组CR为35.4%,总有效率为50%,组间比较差异有显著性意义（P〈0.05）。原发难治AML、复发性AML、M1型、M2型、M5型及由骨髓增生异常综合征（myelody splastic syn-drome,MDS）转化而来的复发、难治性AML的CR率和总有效率,FLAG组均高于CAG组,组间比较差异有显著性意义（P均〈0.05）。2组的血液学不良反应主要是骨髓抑制,非血液学不良反应较少。结论：CAG方案和FLAG方案均为复发、难治性AML的有效治疗方案,但FLAG方案CR率和总有效率高,不良反应可耐受,可进一步扩大临床应用。

Comparison of FLAG regimen with CAG regimen for refractory or relapsed acute myeloid leukemia

Objective：To investigate the efficacy and safety of FLAG and CAG regimen for refractory or released acute myeloid leukemia（AML）.Methods： Seventy-four patients with refractory or released AML in our hospital were divided into FLAG group and CAG group.The efficacy and toxicities were analyzed and compared between the two groups.Results： The complete remission rate（CR） was 61.5% and the overall response（OR） rate was 76.9% in FLAG group.The CR rate was 35.4% and the OR rate was 50% in CAG group.For the patients with primary refractory AML or relapsed AML or refractory or relapsed AML of M1,M2,M5 subtype or those converted from myelodysplastic syndrome（MDS）,the rate of CR and OR in FLAG group was higher than that in CAG group.The main toxicities of these two groups were myelosuppression.Conclusion： FLAG regimen and CAG regimen are both effective for refractory or relapsed AML,but the rate of CR and OR in FLAG group was higher,and the adverse effects from FLAG regimen were well tolerated by patients,so the FLAG regimen can be widely used further.